Press releases

MARLBOROUGH, Mass., Feb. 6, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter ™

Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024. Mike Mahoney, chairman and chief executive officer, will...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis...

Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston...

MARLBOROUGH, Mass. and LAS VEGAS, Jan. 20, 2024 – Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the SOLIS randomized control trial, demonstrating...

MARLBOROUGH, Mass., Jan. 11, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company’s clinical data that will be featured at the 27th North American Neuromodulation...

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass., Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday,...

Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a...

Recent healthcare plan coverage of Intracept® system expands access to vertebrogenic pain treatment for tens of millions of patients MARLBOROUGH, Mass., Nov. 17, 2023 /PRNewswire/ -- Boston...